NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · USD

Starling Oncology, Inc. (STLNW) Stock Analysis

Starling Oncology, Inc. (STLNW) is a stock listed on NASDAQ and quoted in US Dollar.

STLNW

$0.05

−$0.02 (−23.33%)

Sep 4, 2026 · Market close

This is a derivative instrument — a warrant on The Oncology Institute, Inc. (STLN) common stock.

Issuer fundamentals are shown on the issuer page, not here.

View STLN →

Price History

Hover for the daily close. The dotted line marks the period open.

STLNW Key Statistics

As of Sep 4, 2026
Trading
Open
$0.05
Previous Close
$0.07
Volume
2.01K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.44

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

About Starling Oncology, Inc.

Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliative care programs; operates combined community clinics and infusion suites; and operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by patients concurrent with their in-office cancer therapies. It serves adult and senior cancer patients. The company was formerly known as The Oncology Institute, Inc. and changed its name to Starling Oncology, Inc. in August 2026. Starling Oncology, Inc. was founded in 2007 and is headquartered in Cerritos, California.

Visit website →